Cited by 118Parkinson's Disease Mechanisms and TreatmentsMenopause: Health Impacts and TreatmentsEstrogen and related hormone effects

The DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.

Is there a connection between estrogen and Parkinson’s disease?

Shulman, Lisa M.·2002·Parkinsonism & Related Disorders

DOI 10.1016/s1353-8020(02)00014-7

Open this paper in CoChat — free account

Abstract

Increasing evidence suggests that estrogens may protect the nigrostriatal dopaminergic pathway affected in Parkinson's disease (PD). Animal studies show that estrogens influence the synthesis, release, and metabolism of dopamine and can modulate dopamine receptor expression and function. Some clinical studies suggest that PD symptoms may be exacerbated after menopause and delayed or alleviated with hormone replacement therapy, but others have failed to observe positive estrogenic effects. The conflicting findings suggest that several variables, including age, estrogen dose and formulation, and timing and length of dosing period, may determine whether benefits are seen and the nature of these benefits. Further investigation is therefore needed for the relationship between estrogens and the nigrostriatal dopaminergic system.

Integrity signals

Registry

Crossref · 10.1016/s1353-8020(02)00014-7

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Anesthesiology
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,153
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Cell Membrane and Nuclear Estrogen Receptors (ERs) Originate from a Single Transcript: Studies of ER and ER Expressed in Chinese Hamster Ovary Cells
Razandi, M., Pedram, A., Greene, G. L., & Levin, E. R. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0239 · Cited by 1,075
Estrogen Stimulates a Transient Increase in the Number of New Neurons in the Dentate Gyrus of the Adult Female Rat
Tanapat, P., Hastings, N. B., Reeves, A. J., & Gould, E. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-14-05792.1999 · Cited by 994
Estrogens Attenuate and Corticosterone Exacerbates Excitotoxicity, Oxidative Injury, and Amyloid β‐Peptide Toxicity in Hippocampal Neurons
Goodman, Y., Bruce‐Keller, A. J., Cheng, B., & Mattson, M. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66051836.x · Cited by 830
Steroid Receptor Family: Structure and Functions
Carson, M. A., Schrader, W. T., & O’Malley, B. W. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-201 · Cited by 813
Neuroprotection against Oxidative Stress by Estrogens: Structure-Activity Relationship
Behl, C., Skutella, T., Lezoualc’h, F., Post, A., Widmann, M., Newton, C. J., & Holsboer, F. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.4.535 · Cited by 757
Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor
Mermelstein, P. G., Becker, J., & Surmeier, D. J. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-02-00595.1996 · Cited by 627
Membrane estrogen receptors identified by multiple antibody labeling and impeded‐ligand binding
Pappas, T. C., Gametchu, B., & Watson, C. S. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.5.7896011 · Cited by 533

Show all 82 references

Research works printed but not linked: 2

Kraus, 1999, Sex differences for dopaminergic therapy in Parkinson's disease [abstract], Parkinsonism Related Dis, 5, S77
Lapchak, 1998, A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease, Mov Disord, 13, 49

Sorted by citations

Estrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,356
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
Sex differences in Parkinson’s disease
Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.002 · Cited by 521
Role of estrogen receptors in health and disease
Chen, P., Li, B., & Ou-Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839005 · Cited by 339
Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study
Alves, G. W., Müller, B. P., Herlofson, K., Hogenesch, I., Telstad, W., Aarsland, D., Tysnes, O., Larsen, J. O., & for the Norwegian ParkWest study group (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.168211 · Cited by 275
Coffee Consumption, Gender, and Parkinson’s Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen
Ascherio, A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh312 · Cited by 232
Dose–response meta‐analysis on coffee, tea and caffeine consumption with risk of P arkinson's disease
Qi, H., & Li, S. (2013) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12123 · Cited by 246
Postmenopausal Estrogen Use Affects Risk for Parkinson Disease
Currie, L. J., Harrison, M. B., Trugman, J. M., Bennett, J. P., & Wooten, G. F. (2004) · Archives of Neurology · doi:10.1001/archneur.61.6.886 · Cited by 226
Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments
Gao, C., Liu, J., Tan, Y., & Chen, S. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00191-5 · Cited by 223
PI3 kinase/Akt activation mediates estrogen and IGF‐1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease
Quesada, A., Lee, B. Y., & Micevych, P. E. (2008) · Developmental Neurobiology · doi:10.1002/dneu.20609 · Cited by 187
Sex and Gender Differences in Central Nervous System-Related Disorders
Zagni, E., Simoni, L., & Colombo, D. (2016) · Neuroscience Journal · doi:10.1155/2016/2827090 · Cited by 173
Reproductive Steroid Regulation of Mood and Behavior
Schiller, C. E., Johnson, S., Abate, A., Schmidt, P. J., & Rubinow, D. R. (2016) · Comprehensive physiology · doi:10.1002/cphy.c150014 · Cited by 224
The Impact of Estrogen and Estrogen-Like Molecules in Neurogenesis and Neurodegeneration: Beneficial or Harmful?
Bustamante-Barrientos, F. A., Méndez-Ruette, M., Ortloff, A., Luz‐Crawford, P., Rivera, F. J., Figueroa, C. D., Molina, L., & Bátiz, L. F. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.636176 · Cited by 180
Risk of Parkinson disease in women
Ragonese, P., D’Amelio, M., Salemi, G., Aridon, P., Gammino, M., Epifanio, A., Morgante, F., & Savettieri, G. (2004) · Neurology · doi:10.1212/wnl.62.11.2010 · Cited by 158
Age Cutoff for Early‐Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease
Mehanna, R., Śmiłowska, K., Fleisher, J. E., Post, B., Hatano, T., Piemonte, M. E. P., Kumar, K. R., McConvey, V., Zhang, B., Tan, E., et al. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13523 · Cited by 155
Young-onset Parkinson's disease: Its unique features and their impact on quality of life
Mehanna, R., & Jankovic, J. J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.06.001 · Cited by 145
Psychiatric aspects of Parkinson’s disease
Grover, S., Somaiya, M. P., Kumar, S., & Avasthi, A. (2014) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.143197 · Cited by 116
Brain renin-angiotensin system and dopaminergic cell vulnerability
Labandeira-García, J. L., Garrido‐Gil, P., Rodríguez‐Pallares, J., Valenzuela, R., Borrajo, A., & Rodriguez-Perez, A. I. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00067 · Cited by 115
Protective Microglia and Their Regulation in Parkinson’s Disease
Le, W., Wu, J., & Tang, Y. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00089 · Cited by 123
Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human
Jee, H. J., Lee, S. G., Bormate, K. J., & Jung, Y.-S. (2020) · Nutrients · doi:10.3390/nu12103080 · Cited by 111
“7 h), and is mainly excreted by urine after being metabolized in the liver [7].”
Background
Differences in the Presentation and Progression of Parkinson's Disease by Sex
Iwaki, H., Blauwendraat, C., Leonard, H. L., Makarious, M. B., Kim, J. J., Liu, G., Maple‐Grødem, J., Corvol, J., Pihlstrøm, L., van Nimwegen, M., et al. (2020) · Movement Disorders · doi:10.1002/mds.28312 · Cited by 103
Sex differences in Parkinson’s disease
Lubomski, M., Rushworth, R. L., Lee, W., Bertram, K., & Williams, D. R. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.12.016 · Cited by 101
Gender disparities in Parkinson’s disease
Shulman, L. M., & Bhat, V. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.407 · Cited by 96
OESTROGEN AND NIGROSTRIATAL DOPAMINERGIC NEURODEGENERATION: ANIMAL MODELS AND CLINICAL REPORTS OF PARKINSON'S DISEASE
Liu, B., & Dluzen, D. E. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04616.x · Cited by 98
Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort
Bove, R. M., Healy, B. C., Musallam, A., Glanz, B. I., Jager, P. L. D., & Chitnis, T. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515606211 · Cited by 90
Nuclear factor‐kappa B (NF‐κB) in pathophysiology of Parkinson disease: Diverse patterns and mechanisms contributing to neurodegeneration
Dolatshahi, M., Hameghavandi, M. H. R., Sabahi, M., & Rostamkhani, S. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15242 · Cited by 87
Parkinson's disease in women: A call for improved clinical studies and for comparative effectiveness research
Pavon, J. M., Whitson, H. E., & Okun, M. S. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.01.001 · Cited by 84
Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's Disease
Siani, F., Greco, R., Levandis, G., Ghezzi, C., Daviddi, F., Demartini, C., Vegeto, E., Armentero, M., & Blandini, F. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00306 · Cited by 77
Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease
Rodriguez-Perez, A. I., Dominguez‐Meijide, A., Lanciego, J. L., Guerra, M. J., & Labandeira-García, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.004 · Cited by 69
Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease
Rodriguez-Perez, A. I., Valenzuela, R., Villar‐Cheda, B., Guerra, M. J., Lanciego, J. L., & Labandeira-García, J. L. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.015 · Cited by 68
Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson's Disease: A HuGE Review and Meta-Analysis
Ragland, M. F., Hutter, C., Zabetian, C. P., & Edwards, K. L. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp288 · Cited by 64
Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system
Rodriguez-Perez, A. I., Valenzuela, R., Villar‐Cheda, B., Guerra, M. J., & Labandeira-García, J. L. (2011) · Brain · doi:10.1093/brain/awr320 · Cited by 61
Parkinson's disease and pregnancy: An updated review
Seier, M., & Hiller, A. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.05.007 · Cited by 61
l-Dopa-Induced Dyskinesia—Clinical Presentation, Genetics, and Treatment
Kukkle, P. L., Fox, S. H., & Meissner, W. G. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00002-x · Cited by 56
Parkinson's Disease: Mitochondrial Molecular Pathology, Inflammation, Statins, and Therapeutic Neuroprotective Nutrition
KONES, R. J. (2010) · Nutrition in Clinical Practice · doi:10.1177/0884533610373932 · Cited by 57
Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson’s Disease
Labandeira-Garcia, J. L., Rodríguez-Perez, A. I., Villar-Cheda, B., Borrajo, A., Dominguez-Meijide, A., & Guerra, M. J. (2015) · The Neuroscientist · doi:10.1177/1073858414554954 · Cited by 54
Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra.
Labandeira-García, J. L., Rodríguez‐Pallares, J., Villar‐Cheda, B., Rodriguez-Perez, A. I., Garrido‐Gil, P., & Guerra, M. J. (2011) · Europe PMC (PubMed Central) · Cited by 50
The role of the brain renin-angiotensin system in Parkinson´s disease
Labandeira-García, J. L., Labandeira, C. M., Guerra, M. J., & Rodriguez-Perez, A. I. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00410-3 · Cited by 44
Effect of long-term estrogen therapy on dopaminergic responsivity in post-menopausal women—a preliminary study
Craig, M., Cutter, W. J., Wickham, H., van Amelsvoort, T., RYMER, J. M., Whitehead, M. I., & Murphy, D. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.03.008 · Cited by 44
Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson’s disease
Flores‐Cuadrado, A., Saiz‐Sánchez, D., Mohedano‐Moriano, A., Lamas-Cenjor, E., Leon-Olmo, V., Martı́nez-Marcos, A., & Úbeda‐Bañón, I. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-020-00154-7 · Cited by 42
Gender differences in the association between antidepressant use and restless legs syndrome
Baughman, K. R., Bourguet, C. C., & Ober, S. K. (2009) · Movement Disorders · doi:10.1002/mds.22517 · Cited by 38
Gender‐related differences in the human subthalamic area: a local field potential study
Marceglia, S. R. F., Mrakic‐Sposta, S., Foffani, G., Cogiamanian, F. M., Caputo, E., Egidi, M., Barbieri, S., & Priori, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05208.x · Cited by 38
Coronal plane spinal malalignment and Parkinson's disease: prevalence and associations with disease severity
Choi, H. J., Smith, J. S., Shaffrey, C. I., Lafage, V., Schwab, F., Ames, C. P., Matsumoto, M., Baik, J. S., & Ha, Y. S. (2014) · The Spine Journal · doi:10.1016/j.spinee.2014.07.004 · Cited by 37
Reproductive factors and Parkinson's disease: A multicenter case–control study
Nicoletti, A. S. Q., Nicoletti, G., Arabia, G., Annesi, G., Mari, M. D., Lamberti, P., Grasso, L., Marconi, R., Epifanio, A., Morgante, L., et al. (2011) · Movement Disorders · doi:10.1002/mds.23951 · Cited by 37
Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine
Ferraz, A. C., Xavier, L. L., Hernandes, S., Sulzbach, M. L., Viola, G. G., Anselmo-Franci, J. A., Achaval, M., & Cunha, C. D. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03198-6 · Cited by 37
Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.
Labandeira-García, J. L., Rodríguez‐Pallares, J., Rodriguez-Perez, A. I., Garrido‐Gil, P., Villar‐Cheda, B., Valenzuela, R., & Guerra, M. J. (2012) · Europe PMC (PubMed Central) · Cited by 36
Young onset Parkinson's disease. Practical management of medical issues
Calne, S. M., & Kumar, A. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.07.007 · Cited by 36
Gut and Vagina Microbiota Associated With Estrus Return of Weaning Sows and Its Correlation With the Changes in Serum Metabolites
Zhang, J., Liu, M., Ke, S., Huang, X., Fang, S., He, M., Fu, H., Chen, C., & Huang, L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.690091 · Cited by 37
Neuroactive Steroids, Toll-like Receptors, and Neuroimmune Regulation: Insights into Their Impact on Neuropsychiatric Disorders
Balan, I. S., Boero, G., Chéry, S. L., McFarland, M. H., Lopez, A. G., & Morrow, A. L. (2024) · Life · doi:10.3390/life14050582 · Cited by 36
Effects of progesterone administered after MPTP on dopaminergic neurons of male mice
Litim, N., Morissette, M., & Paolo, T. D. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.007 · Cited by 32
A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females
Lin, J.-J., Chen, C., Yueh, K.-C., Chang, C. Y., & Lin, S. Z. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.010 · Cited by 30
Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone
Arad, M., & Weiner, I. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1464-0 · Cited by 30
Predictors of camptocormia in patients with Parkinson's disease: A prospective study from southwest China
Ou, R., Liu, H., Hou, Y., Song, W., Cao, B., Wei, Q., Yuan, X., Chen, Y., Zhao, B., & Shang, H. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.03.020 · Cited by 29
Reproductive factors and Parkinson's disease risk in Danish women
Greene, N., Lassen, C. F., Rugbjerg, K., & Ritz, B. R. (2014) · European Journal of Neurology · doi:10.1111/ene.12450 · Cited by 28
Survival of Huntington’s disease patients in Serbia: longer survival in female patients
Pekmezovic, T. D., Svetel, M. V., Maric, J., Dujmović, I., Dragašević, N., Marković, M. K., Romac, S. P., & Kostić, V. (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9157-7 · Cited by 26
Sexual Dimorphism in Neurodegenerative Diseases and in Brain Ischemia
Zalewska, T., Pawelec, P., Ziąbska, K., & Ziemka‐Nałęcz, M. (2022) · Biomolecules · doi:10.3390/biom13010026 · Cited by 23
Preventive Effects of Soy Meal (±Isoflavone) on Spatial Cognitive Deficiency and Body Weight in an Ovariectomized Animal Model of Parkinson's Disease
Sarkaki, A., Badavi, M., Aligholi, H., & Moghaddam, A. Z. (2009) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2009.1338.1345 · Cited by 22
Effect of Different Doses of Estrogen on the Nigrostriatal Dopaminergic System in Two 6-Hydroxydopamine-Induced Lesion Models of Parkinson’s Disease
Cordellini, M. F., Piazzetta, G., Pinto, K. C., Delattre, A. M., Matheussi, F., Carolino, R. O. G., Szawka, R. E., Anselmo-Franci, J. A., & Ferraz, A. C. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0428-z · Cited by 22
Metallic nanomaterials in Parkinson's disease: a transformative approach for early detection and targeted therapy
Mansour, A., Eldin, M. H., & El-sherbiny, I. M. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02428a · Cited by 22
Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease
Jeong, S., Lee, H. R., Jang, W., Kim, D., Yoo, J. E., Jeon, K. H., Jin, S., Han, K., & Shin, D. W. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.10.030 · Cited by 20
Progesterone exerts a neuroprotective action in a Parkinson’s disease human cell model through membrane progesterone receptor α (mPRα/PAQR7)
Castelnovo, L. F., & Thomas, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125962 · Cited by 20
Mechanisms linking neurological disorders with reproductive endocrine dysfunction: insights from epilepsy research
Cutia, C. A., & Christian-Hinman, C. A. (2023) · Frontiers in neuroendocrinology (Print) · doi:10.1016/j.yfrne.2023.101084 · Cited by 17
Sex as a Determinant of Age-Related Changes in the Brain
Burmistrov, D. E., Gudkov, S. V., Franceschi, C., & Vedunova, M. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137122 · Cited by 23
Chorea gravidarum
Robottom, B., & Weiner, W. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00015-x · Cited by 19
Movement disorders in women: A review
Rabin, M., Stevens‐Haas, C., Havrilla, E., Devi, T., & Kurlan, R. (2013) · Movement Disorders · doi:10.1002/mds.25723 · Cited by 18
Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson’s disease
Cho, B., Choi, S., & Kim, B. C. (2019) · BMC Neurology · doi:10.1186/s12883-019-1427-y · Cited by 19
Alteration of nuclear factor-kappaB pathway promote neuroinflammation depending on the functions of estrogen receptors in substantia nigra after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment
Mitra, S., Ghosh, N., Sinha, P., Chakrabarti, N., & Bhattacharyya, A. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.046 · Cited by 17
Recuperative effect of estrogen on rotenone-induced experimental model of Parkinson’s disease in rats
Makav, M., & Eroğlu, H. A. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-11985-5 · Cited by 16
Postmenopausal effects of intrastriatal estrogen on catalepsy and pallidal electroencephalogram in an animal model of Parkinson's disease
Sarkaki, A., Badavi, M., Nejad, K. H., Gharibnaseri, M. K., & Rahim, F. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.022 · Cited by 15
Fas/FasL-mediated apoptosis in the arcuate nucleus and medial preoptic area of male ArKO mice is ameliorated by selective estrogen receptor alpha and estrogen receptor beta agonist treatment, respectively
Hill, R., Chow, J. D. Y., Fritzemeier, K., Simpson, E. R., & Boon, W. C. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.05.012 · Cited by 15
Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues
Wong, K., Zhou, L., Yu, W., Poon, C. C., Xiao, H.-H., Chan, C.-O., Mok, D. K., & Wong, M. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114096 · Cited by 14
17β-Estradiol/N-acetylcysteine interaction enhances the neuroprotective effect on dopaminergic neurons in the weaver model of dopamine deficiency
Botsakis, K., Theodoritsi, S., Grintzalis, K., Angelatou, F., Antonopoulos, I., Georgiou, C. D., Margarity, M., Matsokis, N. A., & Panagopoulos, N. T. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.068 · Cited by 13
Association between urinary caffeine and caffeine metabolites and stroke in American adults: a cross-sectional study from the NHANES, 2009–2014
Fan, J., Yuan, Y., Zhang, X., Li, W., Ma, W., Wang, W., Gu, J., & Zhou, B. (2023) · Scientific Reports · doi:10.1038/s41598-023-39126-1 · Cited by 15
Paroxysmal Non-Kinesigenic Dyskinesia Caused by the Mutation of MR-1 in a Large Polish Kindred
Friedman, A., Zakrzewska‐Pniewska, B., Domitrz, I., Lee, H.-Y., Ptáček, L. J., & Kwieciński, H. (2008) · European Neurology · doi:10.1159/000165348 · Cited by 12
Alteration in nuclear factor-kappaB pathway and functionality of estrogen via receptors promote neuroinflammation in frontal cortex after 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine treatment
Mitra, S., Ghosh, N., Sinha, P., Chakrabarti, N., & Bhattacharyya, A. (2015) · Scientific Reports · doi:10.1038/srep13949 · Cited by 11
Sex and Parkinson's disease: a world of difference?
Burn, D. J. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.109991 · Cited by 11
Non-genetic factors associated with the risk of Parkinson�s disease in Iranian patients
tabatabaei, N. H. (2013) · Functional Neurology · doi:10.11138/fneur/2013.28.2.107 · Cited by 10
“Good” and “Bad” Microglia in Parkinson’s Disease: An Understanding of Homeostatic Mechanisms in Immunomodulation
Tang, Y., & Le, W. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_4 · Cited by 10
Assessing the association of coffee consumption on the relationship of chronic pain with depression and anxiety
Qin, X., Li, C., Wei, W., He, D., Zhao, Y., Cai, Q., Zhang, N., Chu, X., Shi, S., & Zhang, F. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2175412 · Cited by 9
Reproductive Lifespan and Motor Progression of Parkinson’s Disease
Ou, R., Wei, Q., Hou, Y., Zhang, L., Liu, K., Lin, J., Yang, T., Yang, J., Jiang, Z., Song, W., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206163 · Cited by 7
Animal Approaches to Studying Risk Factors for Parkinson’s Disease: A Narrative Review
Silva, R. H., Lopes-Silva, L. B., Cunha, D. G., Becegato, M. S., Ribeiro, A. M., & dos Santos, J. R. D. C. M. (2024) · Brain Sciences · doi:10.3390/brainsci14020156 · Cited by 8
Endocrine Disruptors (Xenoestrogens): An Overview
Dimogerontas, G., & Liapi, C. A. (2013) · Springer eBooks · doi:10.1007/978-3-642-29687-1_1 · Cited by 9
Aromatase and its inhibition in behaviour, obsessive compulsive disorder and parkinsonism
Boon, W. C., & Horne, M. K. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.031 · Cited by 6
Contribution of Five Functional Loci of Dopamine Metabolism-Related Genes to Parkinson’s Disease and Multiple System Atrophy in a Chinese Population
Chen, Y., Ou, R., Zhang, L., Gu, X., Yuan, X., Wei, Q., Cao, B., Zhao, B., Wu, Y., & Shang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00889 · Cited by 5
Small molecule inhibitors targeting alpha-synuclein aggregation: Progress and future outlook
Hajam, I. B., Ahanger, I. A., Rasool, U., & Dar, T. A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.08.017 · Cited by 4
Sex-dependent immune activation shapes disease progression in a model of Parkinson’s disease
Beauchamp, L. C., Palumbo, L. A., Lanser, T. B., Baig, M., & Cox, L. M. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00809-1 · Cited by 5
Combined inhibition of dopamine D1/D2 receptors induces cognitive and emotional dysfunction through oxidative stress and dopaminergic neuron damage
Li, X., Zhuang, Y., Zhang, Y., Fan, K. K., Chen, X., Chen, X., Liu, X., Sun, J., & Liu, L. (2025) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2025.1621017 · Cited by 3
Dual disease co-expression analysis reveals potential roles of estrogen-related genes in postmenopausal osteoporosis and Parkinson’s disease
Yu, D., Kang, J., Ju, C., Wang, Q., Qiao, Y., Qiao, L., & Yang, D. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2024.1518471 · Cited by 2
Bilateral Oophorectomy or Hysterectomy with Ovarian Conservation and Risk of Parkinson's Disease: A Systematic Review and Meta‐Analysis
Derhab, M., Ellabbad, M. M., Muhammad, S., Hamouda, A. M., Tawela, A., Okar, L., Smith, C. Y., Savica, R., & Rocca, W. A. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70490 · Cited by 2
Involvement of nitric oxide in Parkinson's disease: Emphasis on sex difference in prevalence
Taşkıran, D., Nazlıel, B., İrkeç, C., Kutay, F., & Pöğün, Ş. (2003) · Neuroscience Research Communications · doi:10.1002/nrc.10068 · Cited by 2
Machine learning analysis of population-wide plasma proteins identifies hormonal biomarkers of Parkinson’s disease
Chaudhry, F. F., Kim, T. W., Elemento, O., & Betel, D. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1730550 · Cited by 2
Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 3: Drugs indirectly influencing the dopaminergic system (a review)
Кадиева, M. Г., Тоникович, О. Э., & Муцуева, С. Х. (2005) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-006-0022-x · Cited by 2
Effects of L-dopa on expression of prolactin and synaptotagmin IV in 17-estradiol-induced prolactinomas of ovariectomized hemiparkinsonian rats
Zorović, M., Kolmančič, K., & Živin, M. (2021) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.5491 · Cited by 2
Exploring the relationships between clinical manifestations and sex hormones, thyroid hormones, and menstrual factors in female Parkinson’s disease patients
Wang, F., Wang, F., Zhao, J., Li, J., Li, J., Wang, P., Zhong, Y., & Feng, T. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1573768 · Cited by 2
Ulcerative colitis model triggers gut α-Synuclein aggregation without brain involvement or neuronal loss in female rats
Espinosa‐Oliva, A. M., Vázquez‐Carretero, M. D., Ruiz, R., Roca-Ceballos, M. A., García-Miranda, P., Peral, M. J., Soto, M. S., Herrera, A. J., Venero, J. L., & de Pablos, R. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1637548 · Cited by 1
Insights from a cross-sectional population-based study of 10,929 Australians living with Parkinson's disease: risk factors, comorbidities, and sex differences
Cao, F., McAloney, K., Ogonowski, N. S., García‐Marín, L. M., Díaz‐Torres, S., Flores‐Ocampo, V., Ceja, Z., Chafota, F., Parker, R., Ferguson, M., et al. (2026) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2026.101816 · Cited by 1
MODELO IN VITRO DE PARKINSONISMO EXPERIMENTAL INDUZIDO POR ROTENONA: INVESTIGAÇÃO DE MECANISMOS DE AÇÃO, NEUROPROTEÇÃO E MORTE CELULAR
Filho, M. N. P., & Jorge, A. B. N. (2011) · Cited by 1
MicroRNAs Contribute to the Protective Actions of 17β-Estradiol on the Vascular System
Rigassi, L. (2016) · Zurich Open Repository and Archive (University of Zurich) · doi:10.3929/ethz-a-010737742 · Cited by 1
Parkinson's Disease
Crichton, R. R., & Ward, R. J. (2013) · Wiley eBooks · doi:10.1002/9781118553480.ch06 · Cited by 1

Authors: Shulman, L. M.
Affiliations: University of Maryland, Baltimore (US)
Corresponding author: Shulman, Lisa M.
ORCID: Shulman, Lisa M.
Venue: Parkinsonism & Related Disorders
Publisher: Elsevier BV
Published: 2002-06
Volume: 8
Issue: 5
Pages: 289-295
ISSN: 1353-8020 (ISSN-L)
DOI: 10.1016/s1353-8020(02)00014-7
OpenAlex: W1979867396
Cited by: 118
References: 82
Citations by year: 2026: 6 · 2025: 9 · 2024: 6 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 7 · 2015: 2 · 2014: 8 · 2013: 7 · 2012: 2
FWCI: 0.47
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Parkinsonism & Related Disorders (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords: estrogen, Parkinson's disease
MeSH terms: Estrogens, Female, Humans, Parkinson Disease, Estrogen Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Is there a connection between estrogen and Parkinson’s disease?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks